Savall Brad M, Meduna Steven P, Tays Kevin, Cai Hui, Thurmond Robin L, McGovern Patricia, Gaul Michael, Zhao Bao-Ping, Edwards James P
Janssen Pharmaceutical Research & Development, LLC, 3210 Merryfield Row, San Diego, CA 92121, United States.
Janssen Pharmaceutical Research & Development, LLC, 3210 Merryfield Row, San Diego, CA 92121, United States.
Bioorg Med Chem Lett. 2015 Feb 15;25(4):956-9. doi: 10.1016/j.bmcl.2014.12.027. Epub 2014 Dec 23.
Previously disclosed H4 receptor modulators, the triamino substituted pyridines and pyrimidines, contain a free primary amino (-NH2) group. In this Letter we demonstrate that an exocyclic amine (NH2) is not needed to maintain affinity, and also show a significant divergence in the SAR of the pendant diamine component. These des-NH2 azacycles also show a distinct functional spectrum, that appears to be influenced by the diamine component; in the case of the 1,3-amino pyrimidines, the preferred diamine is the amino pyrrolidine instead of the more common piperazines. Finally, we introduce 3,5-diamino pyridazines as novel histamine H4 antagonists.
先前公开的H4受体调节剂,即三氨基取代的吡啶和嘧啶,含有一个游离的伯氨基(-NH2)基团。在本信函中,我们证明了维持亲和力并不需要环外胺(NH2),并且还表明在侧链二胺组分的构效关系上存在显著差异。这些去-NH2氮杂环也显示出独特的功能谱,这似乎受二胺组分的影响;就1,3-氨基嘧啶而言,优选的二胺是氨基吡咯烷而非更常见的哌嗪。最后,我们引入3,5-二氨基哒嗪作为新型组胺H4拮抗剂。